INOVIO PHARMACEUTICALS, INC. Foreign Pre-Tax Income
INOVIO PHARMACEUTICALS, INC. (INO) reported Foreign Pre-Tax Income of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2025-03-18
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was $0.00.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was -$137.77K.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2022 was -$211.25K.
- INOVIO PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2021 was -$610.32K.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-18 |
| 2023-12-31 | -$137.77K 10-K · filed 2025-03-18 |
| 2022-12-31 | -$211.25K 10-K · filed 2024-03-06 |
| 2021-12-31 | -$610.32K 10-K · filed 2024-03-06 |
| 2020-12-31 | -$225.95K 10-K · filed 2023-03-01 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |